Want to see TCRX full AI Analyst Report?
TCRX Stock Chart & Stats
$0.79
-$0.05(-6.19%)
At close: 4:00 PM EDT
$0.79
-$0.05(-6.19%)
Day’s Range― - ―
52-Week Range$0.72 - $2.57
Previous CloseN/A
Volume1.06M
Average Volume (3M)476.93K
Market Cap
$52.83M
Enterprise Value$118.10
Total Cash (Recent Filing)$100.16M
Total Debt (Recent Filing)$90.89M
Price to Earnings (P/E)―
Beta2.10
Next Earnings
Nov 11, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.91
Shares Outstanding63,502,666
10 Day Avg. Volume455,904
30 Day Avg. Volume476,927
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.05
Price to Sales (P/S)12.58
P/FCF Ratio-0.93
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.00Price Target Upside659.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.08
Revenue Forecast (FY)$7.86M
Bulls Say, Bears Say
Bulls Say
Clinical ProgressThe early TSC-101 clinical signal supports the therapy’s potential in hematologic malignancies. Sustained evidence of donor chimerism and acceptable safety could improve the program’s probability of advancing toward later-stage development.
Manufacturing ReadinessA roughly 90% manufacturing success rate with a commercial-ready process addresses a key cell-therapy execution risk. Repeatable production could support broader clinical development and improve the feasibility of eventual commercialization.
Pivotal Trial PathPreparation for a pivotal Phase 3 study indicates that TSC-101 may be moving beyond early proof-of-concept. Reaching this stage can create a clearer development pathway and strengthen the company’s strategic partnering potential.
Bears Say
Partnership LossThe Amgen termination weakens TScan’s partnership-driven revenue model by eliminating expected success-based economics from the collaboration. It reduces potential non-dilutive funding and increases reliance on internal programs and future financing.
Persistent Cash BurnPersistent operating and free-cash-flow deficits show that the business is not self-funding. Continued clinical investment will likely require additional capital, creating execution risk and potentially increasing dilution before breakeven is reached.
Weak Financial BaseDeclining revenue, large ongoing losses, and rising leverage indicate a weakening financial base. Lower equity and higher debt reduce flexibility, making it harder to absorb development setbacks or fund multiple programs without external capital.
TScan Therapeutics News
TCRX FAQ
What was TScan Therapeutics’s price range in the past 12 months?
TScan Therapeutics lowest stock price was $0.72 and its highest was $2.57 in the past 12 months.
What is TScan Therapeutics’s market cap?
TScan Therapeutics’s market cap is $52.83M.
When is TScan Therapeutics’s upcoming earnings report date?
TScan Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 79 days.
How were TScan Therapeutics’s earnings last quarter?
TScan Therapeutics released its earnings results on Aug 12, 2026. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.253 by $0.023.
Is TScan Therapeutics overvalued?
According to Wall Street analysts TScan Therapeutics’s price is currently Undervalued.
Does TScan Therapeutics pay dividends?
TScan Therapeutics does not currently pay dividends.
What is TScan Therapeutics’s EPS estimate?
TScan Therapeutics’s EPS estimate is -0.28.
How many shares outstanding does TScan Therapeutics have?
TScan Therapeutics has 63,502,666 shares outstanding.
What happened to TScan Therapeutics’s price movement after its last earnings report?
TScan Therapeutics reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.253. Following the earnings report the stock price went down -0.387%.
Which hedge fund is a major shareholder of TScan Therapeutics?
Currently, no hedge funds are holding shares in TCRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TScan Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.00 (659.49% Upside)
$6.00 (659.49% Upside)
Blogger Sentiment
Neutral
TCRX Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.14%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-42.57%
Trailing 12-Months
Company Description
TScan Therapeutics
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
TCRX Stock 12 Month Forecast
Average Price Target
$6.00
▲(659.49% Upside)
Technical Analysis
Zentalis Pharmaceuticals
―
ALX Oncology Holdings
―
Inhibikase Therapeutics
―
Surrozen
―
Instil Bio
―
Ownership Overview
16.81% Insiders
5.23% Mutual Funds
31.98% Other Institutional Investors
41.65% Public Companies and
Individual Investors